Sep. 17 at 4:16 PM
CY200 is being developed to provide a different way of addressing chronic pain.
The scientific rationale presented at PAINWeek included a pathway linking 5-HT2A receptor activation with synaptic remodeling, reduced central sensitization and reduced pain chronification.
Rather than focusing only on the site of pain, the approach being explored through CY200 looks at resetting the central nervous system that plays a major role in persistent pain. As Dr. Jeffrey Gudin explained:
“CRPS is very difficult to treat as it has a central, serotonin mediated, component in addition to the severe pain.”
This framework is helping guide the development of CY200 for CRPS Type 1.
$ENSC $CMPS $DFTX